0358 GMT - ResMed's new bull at Goldman Sachs sees growing awareness of obstructive sleep apnea boosting the breathing-tech developer over the coming years. Analyst Davin Thillainathan tells clients in a note that awareness of the condition is rising thanks to wearable tech such as smart watches, patients seeking obesity treatment through medication, and potentially the use of AI to assist with diagnosis. This underpins what Thillainathan says should be solid growth at ResMed's devices segment over the next three years. He estimates that 25%-30% of U.S. patients with obstructive sleep apnea have tried continuous positive airway pressure therapy over the past 10 years. GS puts a buy rating and A$48.90 target price on the stock, which is up 1.5% at A$38.10. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
January 16, 2025 22:58 ET (03:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。